Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.8.3607

The CCND1 G870A Gene Polymorphism and Brain Tumor Risk: a Meta-analysis  

Qin, Ling-Yan (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Zhao, Li-Gang (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Chen, Xu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Li, Ping (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Yang, Zheng (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Mo, Wu-Ning (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.8, 2014 , pp. 3607-3612 More about this Journal
Abstract
Background: In recent years, numerous studies have been performed to investigate the CCND1 G870A gene polymorphism impact on brain tumors susceptibility. Unfortunately, the results of previous studies were inconsistent. Therefore, we performed a meta-analysis to derive a more precise estimation of any association. Materials and Methods: We conducted a search in PubMed, Embase and CNKI covering all published papers up to November, 2013. Odds ratios (ORs) and their 95% confidence intervals (95%CIs) were applied to assess associations. Results: A total of 6 publications including 9 case-control studies met the inclusion criteria. The pooled ORs for the total included studies showed significant association among comparison A vs G (OR= 1.246, 95%CI= 1.092-1.423, p= 0.001), homozygote comparison AA vs GG (OR= 1.566, 95%CI= 1.194-2.054, p= 0.001), heterozygote comparison AG vs GG (OR= 1.290, 95%CI= 0.934-1.782, p= 0.122), dominant model AA/GA vs GG (OR= 1.381, 95%CI= 1.048-1.821, p= 0.022) and recessive model AA vs GA/GG (OR= 1.323, 95%CI= 1.057-1.657, p= 0.015) especially in glioma. Conclusions: CCND1 G870A polymorphism may increase brain tumor risk, especially for gliomas. However, more primary large scale and well-designed studies are still required to evaluate the interaction of CCND1 G870A polymorphism with brain tumor risk.
Keywords
Brain tumors; cyclin D1 gene; polymorphism; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
2 Evan GI, Vousden KH (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-8.   DOI   ScienceOn
3 Galbraith RF (1988). A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med, 7, 889-94.   DOI   ScienceOn
4 Gazioglu NM, Erensoy N, Kadioglu P, et al (2007). Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas. Med Sci Monit, 13, 457-63.
5 Inskip PD, Linet MS, Heineman EF (1995). Etiology of brain tumors in adults. Epidemiol Rev, 17, 382-414.
6 Kong S, Amos CI, Luthra R, et al (2000). Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res, 60, 249-52.
7 Liu J, Liao Q, Zhang Y, et al (2012). Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis. Tumour Biol, 33, 1467-76.   DOI
8 Betticher DC, Thatcher N, Altermatt HJ, et al (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene, 11, 1005-11.
9 Akkiz H, Bayram S, Bekar A, et al (2010). Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: casecontrol study. Cancer Epidemiol, 34, 298-302.   DOI   ScienceOn
10 Bala S, Peltomaki P (2001). CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res, 61, 6042-5.
11 Bedewy AM, Mostafa MH, Saad AA, et al (2013). Association of cyclin D1 A870G polymorphism with two malignancies:acute lymphoblastic leukemia and breast cancer. J BUON, 18, 227-38.
12 Bondy ML, Scheurer ME, Malmer B, et al (2008). Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer, 113, 1953-68.   DOI   ScienceOn
13 Cander S, Erturk E, Karkucak M, et al (2012). Effect of cycline D1 (CCND1) gene polymorphism on tumor formation and behavior in patients with prolactinoma. Gene, 509, 158-63.   DOI   ScienceOn
14 Chen B, Cao L, Yang P, et al (2012). Cyclin D1 (CCND1) G870A gene polymorphism is an ethnicity-dependent risk factor for digestive tract cancers: a meta-analysis comprising 20, 271 subjects. Cancer Epidemiol, 36, 106-15.   DOI   ScienceOn
15 Chen X, Zhao T, Li L, et al (2012). CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population. DNA Cell Biol, 31, 1107-13.   DOI   ScienceOn
16 Zeybek U, Yaylim I, Ozkan NE, et al (2013). Cyclin D1 gene G870A variants and primary brain tumors. Asian Pac J Cancer Prev, 14, 4101-6.   과학기술학회마을   DOI   ScienceOn
17 Wang L, Habuchi T, Mitsumori K, et al (2003). Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer, 103, 116-20.   DOI   ScienceOn
18 Wang Y, Li Z, Liu N, et al (2014). Association between CCND1 and XPC polymorphisms and bladder cancer risk: a metaanalysis based on 15 case-control studies. Tumour Biol, 35, 3155-65.   DOI   ScienceOn
19 Yang Y, Wang F, Shi C, et al (2012). Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case-control studies. Plos One, 7, 36813.   DOI
20 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
21 Qiuling S, Yuxin Z, Suhua Z, et al (2003). Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis, 24, 1499-503.   DOI   ScienceOn
22 Solomon DA, Wang Y, Fox SR, et al (2003). Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem, 278, 30339-47.   DOI   ScienceOn
23 Rajaraman P, Wang SS, Rothman N, et al (2007). Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev, 16, 1655-61.   DOI   ScienceOn
24 Sherr CJ (1995). D-type cyclins. Trends Biochem Sci, 20, 187-90.   DOI   ScienceOn
25 Simpson DJ, Fryer AA, Grossman AB, et al (2001). Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis, 22, 1801-7.   DOI   ScienceOn
26 Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 469.   DOI   ScienceOn
27 Tobias A, Campbell MJ (1999). Modelling influenza epidemics in the relation between black smoke and total mortality. A sensitivity analysis. J Epidemiol Community Health, 53, 583-4.   DOI
28 Vogelstein B, Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med, 10, 789-99.   DOI   ScienceOn
29 Donnellan R, Chetty R (1998). Cyclin D1 and human neoplasia. Mol Pathol, 51, 1-7.   DOI   ScienceOn
30 Daly AF, Rixhon M, Adam C, et al (2006). High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab, 91, 4769-75.   DOI
31 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
32 Diehl JA (2002). Cycling to cancer with cyclin D1. Cancer Biol Ther, 1, 226-31.   DOI
33 Sadetzki S, Flint-Richter P, Starinsky S, et al (2005). Genotyping of patients with sporadic and radiationassociated meningiomas. Cancer Epidemiol Biomarkers Prev, 14, 969-76.   DOI   ScienceOn
34 Catarino R, Coelho A, Nogueira A, et al (2012). Cyclin D1 polymorphism in non-small cell lung cancer in a Portuguese population. Cancer Biomark, 12, 65-72.
35 Gijtenbeek JM, Boots-Sprenger SH, Franke B, et al (2005). Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol, 74, 261-6.   DOI